A GAITS-driven Gap-to-Deliverable Accelerator for Early-Stage Neurotechnology: Design and Early Outcomes of the Blueprint MedTech Seedling Program (Frontiers in Medical Technology)

Summary

• Blueprint MedTech completed two Seedling cohorts (17 and 22 teams) and launched a third cohort of 19 teams.p.3
• 13/17 teams (76.5%) in Cohort 1 and 18/22 teams (81.8%) in Cohort 2 advanced to Deep Dive evaluation after Seedling.p.3
• Team-composition gaps were identified in 48 teams (82.8%) across all 58 teams.p.9
• Commercialization gaps were identified in 47/58 teams (81.0%).p.9
• Cohort 1 and Cohort 2 progression rates did not differ statistically (Fisher exact p = 0.709).p.2

Key insights

1. The combined progression rate was 79.5% with an exact 95% CI of 63.5%-90.7%.p.11
2. Each team receives a dedicated Regulatory Consultation of 90 min with an FDA medical device regulatory specialist.p.6
3. The program supported 58 teams: 17 in Cohort 1 and 22 in Cohort 2.p.8
4. Of Cohort 2 teams, 10 (45.5%) included women.p.10
5. Small businesses with 50 or fewer employees accounted for 16/58 teams (27.6%).p.11
6. The 79.5% rate applies only to this selected Seedling population and cannot be read as a population-level translation rate or a causal program effect.p.15